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bFGF and its low affinity receptors in the pathogenesis of HIV-
associated nephropathy in transgenic mice. HIV-associated nephropathy
is characterized by extensive tubulointerstitial disease with epithelial cell
injury, microcystic proliferation, and tubular regeneration with glomeru-
losclerosis. To explore the role of bFGF as a mediator of HIV-induced
interstitial disease, we utilized an HIV transgenic mouse model that
manifests clinical and histological features observed in patients. In trans-
genie mice, simultaneous renal epithelial cellproliferation and injury were
detected in vivo. In areas of microcystic proliferation, immunoreactive
bFGF colocalized with extracellular matrix. Kidneys from transgenic mice
had increased bFGF low affinity binding sites, particularly in the renal
interstitium. In vitro, transgenic renal tubular epithelial cells proliferated
more rapidly and generated tubular structures spontaneously, in marked
contrast to nontransgenic renal cells where these pathologic features could
be mimicked by exogenous bFGF. These studies suggest that renal bFGF
and its receptors play an important role in the pathogenesis of HIV-
associated nephropathy.
Enlarged kidneys with histopathological evidence of renal
tubular epithelial cell (RTEC) injury, microcystic proliferation,
and tubular regeneration are distinctive features of HIV-associ-
ated nephropathy (HIVAN). Mesangial hyperplasia, focal seg-
mental and global glomerular sclerosis and reactive hyperplasia of
the renal epithelium are observed as well [1—4]. Although the
fundamental mechanisms responsible for these proliferative and
degenerative changes are unknown, many hypotheses have been
proposed; the glomerular or tubular abnormalities characteristic
of HIVAN could result from replicating virus in renal cells [5],
associated drug toxicity [6, 7], coexistent opportunistic infections
[6, 8, 9], and genetic predisposition [10]. In addition, it has been
suggested that circulating mediators, including cytokines, viral
proteins, or immune complexes [2—8, 111 may act upon renal
parenchymal cells to induce the characteristic histological changes
of HIVAN.
Recently, we have described HIVAN in mice made transgenic
for a subgenomic proviral HIV-1 construct [12, 13]. Transgenic
mice experience progressive renal disease that is both histologi-
cally and clinically similar to that of patients infected with HIV-1.
In these mice, renal disease presents with proteinuria and
progresses rapidly to end-stage disease [13]. Kidneys are enlarged
and there is histologic evidence of glomerulosclerosis and severe
microcystic tubular dilatation [12, 13].
Increasing evidence supports an important role for members of
the fibroblast growth factor (FGF) family in proliferative diseases
associated with HIV-1 infection. The oncogene hst/K-FGF which
encodes FGF-4, a growth factor that is highly mitogenic for
fibroblasts, was discovered by transfection of Kaposi's sarcoma
DNA into NIH 3T3 cells [14]. Another gene product related to
the FGF family int-2 is overexpressed in Kaposi's sarcoma cells
and may play a role in stimulating local angiogenesis [15].
Immunoreactive bFGF has been detected in Kaposi's sarcoma
lesions in AIDS patients by immunocytochemistry [16, 17]. This
member of the FGF family has been clearly shown to be present
in renal tissues as well [18—20].
Basic FGF is a highly conserved 18 kDa cationic protein that
belongs to the family of heparin binding growth factors [21]. It is
primarily a cell-associated protein with important roles in fetal
development, neovascularization, wound healing, and neuronal
and smooth muscle cell growth [18, 21, 22]. In the fetal mouse
kidney, bFGF is localized within the basement membranes sur-
rounding renal tubules [18] and it is mitogenic for renal epithelial
cells [23, 24]. These findings suggest an important role for bFGF
during renal tubular development. A role in renal pathogenesis,
however, remains less clearly defined. bFGF released by injured
mesangial cells in a rat model of immunologically-induced gb-
merulonephritis stimulates the proliferation of mesangial cells
[25]. In addition, in diseases characterized by renal epithelial
proliferation and injury such as renal and bladder tumors [26—28],
increased bFGF can be detected in the urine suggesting that
during this process bFGF can be released from cells. Further-
more, the role of bFGF in HIV pathogenesis remains unclear. In
the present study, we present evidence to support an important
role for bFGF and its receptors in the pathogenesis of HIVAN.
Methods
Transgenic mice
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We have introduced into mice as a transgene, a replication
defective HIV-1 proviral construct lacking the gag and pol genes,
pNL4-3:d1443 [12, 13]. This construct contains the viral long
terminal repeats (LTRs) and encodes envelope, the accessory
759
w
 
760 Ray et al: bFGF in HR/-associated nephropathy
Fig. 1. Comparison of kidney size and renal histology in control (N) and transgenic (T) mice. As shown in panels A and B, transgenic kidneys were enlarged
when compared with normal controls. Control and transgenic kidneys are shown at higher magnification (160x) in panels C and D, respectively. Typical
interstitial features of HIV associated nephropathy in man were observed in transgenic mouse kidneys (panel D) with tubular dilatation, microcyst
formation (*), and the presence of proteinaceous casts in luminal fluid. Transmission electron micrographs of renal epithelial cells are shown from
control (E) and transgenic (F) mouse kidneys. In normal proximal renal tubular epithelial cells, microvilli (MV), mitochondria (MT), lysosomes (LV),
basal infolding of cell membranes (BI), basal lamina (arrowhead) and the nucleus (NU) were observed (panel F). An epithelial cell from transgenic
kidney demonstrated degeneration (arrowhead), absence of microvilli, and scarcity of cellular organella (panel F). Proteinaceous luminal fluid (FL) and
degenerative cell debris (DB) were also visible. Original magnification was 7,930x.
genes viJ vpr, and vpu and the regulatory genes tat, rev, and nef.
Three transgenic lines with identical renal disease have been
characterized in detail [12]. Southern blots indicate that each line
bears multiple proviral copies located at different integration Sites,
Only one of these lines, TgN(pNL43dl4)FOlLom (referred to as
Tg26), has been sustained in long-term breeding [13].
Quantitation of kidney DNA and protein content
Control and transgenic frozen kidneys were minced and pro-
cessed in a solution of proteinase K and sodium dodecyl sulfate.
Samples were deproteinized by successive phenol/chloroform!
isoamyl alcohol extraction. DNA was recovered by ethanol pre-
cipitation, dried, and quantified [29] and protein concentration
was measured in kidney homogenates [30].
Immunolocalization of bFGF in renal tissue
Immunohistochemistry was performed as previously described
using polyclonal rat and human bFGF antibodies raised in rabbits
and provided by Dr. Andrew Baird (Whittier Institute, La Jolla,
CA) [18]. To facilitate penetration of the antibody into tissue, the
sections were then washed in phosphate buffered saline (PBS) and
treated with 1 mg/ml of hyaluronidase (type V: Sigma) buffered at
pH 5.5 with 0.1 M sodium acetate containing 0.15 M NaC1, for 30
minutes at 37°C. Specific controls included: (1) substitution of
normal rabbit sera for the primary antibody; (2) omitting the
primary antisera; and (3) extracting sections with 2.0 M NaCl prior
to the immunohistochemistry procedures.
Extraction of bFGF from renal tissue
bFGF was extracted from kidney samples as previously de-
scribed [19]. Briefly, kidney samples were homogenized in 2%
SDS/solubilization buffer (20 mri Tris-HCI, 1 mM EDTA, 1 mM
EGTA pH 7.4, 1 mri PMSF, 1 rg/ml aprotinin, 1 g/ml leupeptin,
and 1 p.g/mI pepstatin A) centrifuged at 20,000 rpm, and incu-
bated with heparin Sepharose 100 j.d/ml for 18 hours. Samples
were extracted with 2 M NaCl. For analysis of the composition of
the extracts, samples were reduced with 50 mi dithiothreitol and
electrophoresed through a 12.5% denaturing polyaciylamide gel.
The electrophoresed proteins were transferred to nitrocellulose
filters by electroblotting and were immunostained with a 1:1000
dilution of the bFGF rabbit polyclonal antibody.
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Fig. 1. Continued.
Preparation and analysis of RNA poly-dT column (Stratagene, La Jolla, California, USA) according
Total cellular RNA was extracted from cultured cells [31]. to the manufacturer's instructions. For Northern analysis, polyA+
PolyA+ mRNA was isolated from total RNA using a cellulose (2 g) RNA was resolved on agarose/formaldehyde gels and
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Fig, 1. Continued.
blotted to nylon membranes using positive pressure (Posiblot,
Stratagene) [13]. RNA was cross linked by UV light, and mem-
branes were then pre-incubated in a buffer composed of 50%
formamide, 0.1% SDS, 5X SSPE, 100 jig/mI sheared salmon
sperm DNA, and 2X Denhardt's solution for two hours at 42°C.
[32P]-labeled cDNA probes (10 cpm/filter) were hybridized for 18
hours at 42°C in the above buffer containing 10% dextran sulfate.
After hybridization, the filters were washed twice in 6)< SSPE,
Fig. 2. Immunolocalization of
bFGF in control and transgenic
fetal kidney. Fetal kidney from
transgenic mouse stained with
normal rabbit serum as an
antibody control (A). Fetal kidney
from transgenic mouse
demonstrated positive staining
with an anti-bFGF antibody (2.5
jgIml) that was evident in the
extracellular matrix surrounding
renal tubules (B). No significant
differences in bFGF staining
between nontransgenic control
(C) and transgenic (D) fetal
mouse kidney were observed.
Original magnification in panels
A and B was 640X and in panels
C and D was 320X.
Fig. 3. Immunolocalization of
bFGF in adult kidney sections from
control and transgenic mice. bFGF
staining was absent in renal
medulla of 35-day-old (A) and
60-day-old (B) control mice.
Immunoreactive bFGF was
localized to major renal arteries
in control mice (C). Basic FGF
staining was detected in the
extracellular matrix surrounding
renal tubules and microcysts in
35-day-old (D) and 60-day-old
transgenic mice (E and F).
Original magnification in panels
A, B, D, and E was 160X, in
panel C 320X, and in panel F
640x.
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Heights, Illinois, USA) at 4°C for two hours. Nonspecific binding
was determined by incubating sections with 5 4itM unlabeled bFGF
plus 30 j.tg/ml heparin (Fisher Scientific, Fair Lawn, New Jersey,
USA) or 300 p.g/ml heparin alone. Heparin was used to displace
binding because addition of unlabeled bFGF alone did not
completely displace labeled bFGF [36]. After incubation, the
slides were rinsed consecutively four times for one minute each in
fresh binding buffer (4°C). Binding to low affinity sites was
detected after washing tissue sections with 2 M NaCI, 20 mM
HEPES, pH 7.4 for one minute. Finally, kidney sections were
washed in ice-cold water and dried under cold forced air. Film
exposure time ranged from one to four days at room temperature.
Films were developed with D19 Kodak developer for five minutes
at 4°C. In each experiment, equal amounts of iodinated growth
factor or heparin were added to control or transgenic kidney
sections, incubated under the same conditions, and autoradio-
graphs were exposed for equal lengths of time. Differences in
binding were determined by optical density of the autoradiograms
by computerized microdensitometry in specific kidney areas of
0.22 mm2 as described before [34]. Protein content of the specific
areas used for receptor quantification in kidney was determined
by a densitometric procedure described previously [34].
Fig. 4. bFGF Western blot analysis of normal and transgenic kidney e.stracts.
Basic FGF was extracted from normal (lane 1) and transgenic (lane 2)
kidney homogenates, and concentrated by adsorption on to heparin-
sepharose as described in Methods. Each sample containing 60 sg of
protein was reduced with 50 mrvi dithiothreitol an I electrophoresed
through a 12.5% denaturing polyacrylamide gel. The electrophoresed
proteins were transferred to nitrocellulose filters by electroblotting and
were immunostained with a 1/1000 dilution of bFGF rabbit polyclonal
antibody. Recombinant bFGF (50 ng, Biosource International) is provided
as a positive control (lane 3). bFGF was not detected in kidney extracts
from normal control mice that were 60 days old (lane 1). In transgenic
mouse kidneys, however, a bFGF immunoreactive band (large arrow) was
detected co-migrating with control human recombinant bFGF (lanes 2
and 3, respectively). Two additional weakly immunoreactive bands could
be detected above and below the major band (arrowheads), which also
co-migrated with equivalent bands in the recombinant bFGF lane. The
larger molecular weight bands in lanes 2 and 3 are consistent with previous
reports that bFGF can exist as a dimer under SDS and reducing
conditions. The identity of the smaller molecular weight band is unknown.
0.1% SDS for 15 minutes at room temperature, twice in lx SSPF,
0.1% SDS for 15 minutes at room temperature, and twice in 0.1 x
SSPE, 0.1% SDS for 15 minutes at 45°C. The probe specific for all
HIV-1 mRNAs was a nef eDNA 1.1kb BamHI fragment from
HIV-1HxB2 (NIAID Research and Reference Reagent Pro-
gram). This probe overlaps the proviral 3' LTR and is, therefore,
expected to hybridize will all proviral mRNA [32]. The bFGF
probe was a 0.8 kb EcoRI fragment from a cDNA 'ione [33].
bFGF in vitro autoradiography
Mouse kidneys were dissected and immediately frozen in
isopentane on dry ice. Frozen mouse kidney sections (16 j.m)
were cut in a cryostat at — 14°C, mounted onto cold gelatin-coated
glass microscope slides, and stored under vacuum at 4°C for 12
hours. In vitro autoradiography was performed 's described
previously [34, 35]. Briefly, sections were preincubated for 15
minutes in binding buffer (DMEM, 20 mrvi HEPES at pH 7.4, and
0.15% gelatin) followed by incubation in the same buffer contain-
ing 2, 5, or 10 ng!ml [1I]-bFGF (Amersham Corp., Arlington
Cell culture and proliferation assays
Primary cultures of RTECs were obtained from control and
transgenic mice using standard methods [37]. Renal medullary
tissue was minced and passed through serial sieves. Fractions
containing tubular fragments were washed with Hanks balanced
salt solution, and digested with 0.1% collagenase (Type IV-S,
Sigma, St. Louis, Missouri, USA) for 30 minutes at 37°C. The
released cells were plated onto collagen-coated plastic dishes in
Dulbecco's modified Eagle's medium (Biofluids, Rockville, Mary-
land, USA) supplemented with insulin (5 jig/mI), transferrin (5
jig/mi), selenium (5 ng/ml), hydrocortisone (36 ng/ml), triiodothy-
ronine (4 pg/ml), and epidermal growth factor (10 ng/ml).
At confluence, these cells exhibited characteristic epithelial
morphology, growing in a monolayer with a cobble-stone appear-
ance. Confluent RTECs stained positively for keratin and formed
"domes." They lacked extensive actin intermediate filaments
(characteristic of fibroblasts) or Factor Vill-related antigen (char-
acteristic of endothelial cells). Transgenic renal fibroblasts were
isolated by clonal dilution from cells from the renal medulla [38].
NIH 3T3 cells were grown in DMEM containing 10% calf serum
(Gibco, Grand Island, New York, USA). Bovine aortic endothe-
ha! cells or human umbilical endothelial cells (provided by Dr. D,
Grant NIDR/NIH) were grown in tissue culture as previously
described [36, 39, 40].
Heparin-sepharose (Pharmacia Diagnostics, Uppsala, Sweden)
column chromatography (column size 1 ml) was performed as
previously described [18—201. Briefly, 3 ml of concentrated con-
ditioned medium (5 x) was applied to the column and washed
with 20 mM Tris-HC1 (pH 7.4). The column was eluted with a
linear gradient of 0.2 to 2.0 M NaCl in Tris-HCI (pH 7.4). Each
fraction was concentrated fivefold by Centricon 10 microconcen-
trators (Arnicon, Beverly, Massachusetts, USA) with a molecular
weight cut off of 10 kDa. Concentrated samples (20 jil) were
assayed for mitogenic activity by [3H] thymidine incorporation of
target cells as described previously [41]. Briefly, cells were made
quiescent for 24 to 48 hours in the absence of serum or other
growth factors and pulsed with [3H]thymidine for 6 to 24 hours.
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Fig. S. In vitro autoradiography for bFGF binding sites using 1125!] -bFGF. bFGF binding sites in control kidney sections from 60-day-old mice localized
to glomeruli in the renal cortex (C) and vasa recta in the renal medulla (M). In transgenic kidney, the distribution of bFGF binding sites was similar
but increased, particularly in the renal interstitium (A). In transgenic kidney, higher affinity binding sites, detected in the presence of heparin (30 sgIml),
were found predominantly in vasa recta and glomeruli (B). bFGF binding could be displaced completely at a higher heparin concentration (300 g/ml)
suggesting that all renal bFGF binding sites were sensitive to heparin displacement (C). These findings were identical in 7 control and transgenic mice.
After that period, the cells were precipitated with 5% TCA and
solubilized with SDS. Aliquots were counted and results were
expressed in counts per minute (cpm).
Growth of renal tubular epithelial cells on matrigel
For regeneration experiments, RTECs were cultured on matri-
gel (provided by Dr. Hynda Kleinman), a reconstituted basement
membrane extracted from EHS mouse sarcoma tumor as previ-
ously described [40]. Plastic culture wells (16 mm) were coated
with matrigel, 250 j.tl of a 10 mg/mi solution and the matrigel was
allowed to solidify at 37°C for one hour. RTECs (55,000 cells/well)
from control and transgenic mice were cultured in DMEM
without serum, heparin, or growth factors. Additionally, other
nontransgenic RTECs were pretreated with bFGF (20 ng/ml for
24 hr) prior to plating on matrigel. Twenty-four hours after
culturing RTECs on matrigel, the number of formed tubules was
counted in 5 microscopic fields (2X) of 10 different wells. In some
cultures, cells were fixed in glutaraldehyde and analyzed by
transmission electron microscopy.
Statistical analysis
Results are expressed as the mean SD ofvalues obtained in
triplicate from at least three different experiments. Difference
between groups was compared by Student's t-test. P values less
than 0.05 were considered significant. When more than two means
were compared, significance was determined by one way analysis
of variance followed by multiple comparisons using the Student-
Neuman-Keul's test.
Results
Renal disease in HIV transgenic mice
Tubulointerstitial disease is the most striking feature of the
transgenic kidney with varying degrees of tubular distortion and
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Fig. 6. Spontaneous proliferation of renal tubular epithelial cells (RTECs) from control and transgenic mice. DNA synthesis (thymidine incorporation) of
primary cultures of RTECs is shown in panel A. Equal number of control and transgenic RTECs were plated as described in methods. After 6 days in
culture, cells were incubated with 1 jsCi [3H]-thymidine for 24 hours. Spontaneous proliferation of transgenic RTECs was significantly greater than
control cells. Similar results were obtained in four separate experiments with cells isolated from different animals. The asterisk indicates P < 0.001.
Phase contrast light micrographs of confluent RTECs isolated from 60-day-old nontransgenic mice (B) and transgenic mice with renal disease (C) are
shown. Increased dome formation, a characteristic feature of RTECs, is indicated by the arrowheads.
dilatation as well as simultaneous evidence of cell injury, regen-
eration, and proliferation. Proliferation of renal tissue was evident
even by gross pathological observation at 60 days of age; kidneys
were enlarged with a cobblestone appearance of the surface (Fig.
lit). Tubulointerstitial distortion was dramatic and characterized
by microcyst formation (Fig. 1 B, C, D). In addition to tubular
degeneration, there was evidence of coexistent regeneration with
a greater number of nuclei and mitotic figures in renal intersti-
tium. By 60 days of age, kidney weights were significantly in-
creased in transgenic kidneys when compared to littermate con-
trols (220 28 vs. 151 21 respectively; P < 0.05). Both protein
and DNA content of transgenic kidneys were significantly in-
creased by an average of 24% and 25%, respectively, when
compared to control. Immunostaining for proliferating cell nu-
clear antigen (PCNA) showed a greatly increased number of
proliferative cells including RTECs, spindle-shaped interstitial
cells, and in some sections, mononuclear cells in perivascular
aggregates. PCNA positive cells and mitotic figures were found in
areas of microcystic dilation and bFGF localization (data not
shown).
Renal tubular epithelial cell injray
To determine the ultrastructural characteristics of RTEC, we
examined the renal epithelium by transmission electron micros-
copy. There was striking focality of the injury process. As shown in
Figure 1 F and F, RTECs revealed evidence of degenerative
changes with decreased number of mitochondria, mitochondrial
swelling with loss of cristae, and tubular atrophy with loss of
microvilli. These cells were generally found adjacent to normal
cells.
Distribution of bFGF in renal tissues
To explore the distribution of bFGF in transgenic kidneys, we
performed immunohistochemistry using transgenic and control
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Fig. 7. Characterization of bFGF-like activity in conditioned medium from
transgenic renal tubular epithelial cells (RTECs) after heparin-sepharose
purification. Several cell types were used to characterized the proliferative
effects of eluate fractions. All mitogenic effects were tested in the absence
of heparin. The mitogenic effect of a concentrated fraction (5 x) eluted
from a heparin-Sepharose column with a 1.5 to 2.0 M NaCI gradient is
shown in panel A. Subconfluent transgenic RTECs were used as target
cells. A similar fraction eluted from the heparin-Sepharose column was
used to assay proliferative response of subconfiuent rat aortic smooth
muscle cells (B) and subconfluent bovine aortic endothelial cells (C). A
1:20 dilution of a polyclonal rabbit antibody to bFGF neutralized the
proliferative effects of this fraction. The mitogenic effect of bFGF (20
nglml, Biosource International) on transgenic RTECs in subconfiuent
primary culture is shown in panel D. No additional growth factors or
heparin were added to RTEC cultures. The asterisk indicates significance
at P < 0.05. The expression of bFGF and the HIV-1 transgene by RTECs
isolated from 60-day-old mouse kidney and analyzed by Northern blot is
shown in panel E. A 6.8 kb transcript (arrowhead) corresponding to bFGF
was detected in transgenic RTECs. RTECs also expressed HIV-1 mRNA
of the three expected size classes, 2kb, 4kb, and 7 kb that correspond to
multiply spliced, singly-spliced, and full-length transgene mRNAs, respec-
tively.
kidneys at various ages. During renal development, bFGF could
be detected easily in the interstitium surrounding renal tubules
(Fig. 2 B, C, D). No significant differences were present between
control and transgenic fetal kidneys (Fig. 2 C and D). At 35 days
of age, however, there were marked differences in the distribution
of bFGF (Fig. 3). bFGF was not detected in the interstitium of 35
day old control animals (Fig. 3A). With the development of
interstitial renal disease in 35-day-old transgenic mice, bFGF
could be detected surrounding tubules (Fig. 3D). At 60 days of
age, bFGF was significantly increased in extracellular matrix
surrounding areas of microcystic dilatation and in areas of inter-
stitial proliferation in transgenic mice (Fig. 3 E, F). In age-
matched control mice, no bFGF was detected in renal interstitium
(Fig. 3B). Normal localization of bFGF in medullary renal arteries
was detected in sections from adult nontransgenic animals (Fig.
3C).
Quantitation of renal bFGF
To determine whether bFGF was increased in renal extracts of
diseased transgenic kidneys in vivo, we performed Western blot
analysis with transgenic and control kidney extracts (Fig. 4). Three
bFGF immunoreactive bands were detected in protein extracts
from transgenic mouse kidney that comigrated with recombinant
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Fig. 8. Tubule regeneration by renal tubular epithelial cells (RTECs) in
culture. RTECs isolated from control mice remained round in shape
without evidence of spreading after 24 hours of culture on a matrigel
substrate (A). In contrast, transgenic RTECs (B) or RTECs isolated from
nontransgenic control mice that were pre-treated with bFGF (C) formed
tubular structures on matrigel. Cells were photographed using Hoffman
modulation contrast on a Nikon inverted light microscope (magnification
560X). Transmission electron microscopy of a tubular structure formed by
transgenic RTECs is shown in panel D. The tubule formed in vitro had a
patent lumen (L) with cellular debris (DB), a basement membrane
(arrowheads), and tight junctions (arrows) (original magnification
7,930X).
bFGF; bFGF was not detected by Western blot in control kidneys.
By Northern analysis, expression of bFGF mRNA was very low
and no difference in steady state mRNA could be detected (data
not shown).
bFGF low affinily binding sites in renal tissue
Since bFGF binds to components of the extracellular matrix,
particularly heparan sulfate proteoglycans, we examined whether
the increased accumulation of bFGF was due to its binding to
these low affinity sites in renal tissue. To determine the renal
distribution of bFGF low affinity binding, we performed experi-
ments on frozen renal sections using [1251]-bFGF. Total bFGF
binding in renal cortex and medulla was significantly increased in
the transgenic kidneys (Fig. 5A) when compared to controls (Fig.
5 control). Binding to these sites could not be completely dis-
placed by even a 100-fold excess of unlabeled bFGF, suggesting a
very large reservoir of bFGF low affinity binding sites (data not
shown). When sections were incubated in the presence of labeled
bFGF and low concentrations of heparin (30 g/ml heparin),
bFGF binding to low affinity receptors was significantly reduced
(Fig. 5B) when compared to sections incubated without heparin
(Fig. 5A). Higher affinity binding sites were found overlying renal
glomeruli and along the vasa recta in renal medulla (Fig. SB).
These higher affinity binding sites were significantly increased in
the renal cortex and medulla of transgenic kidneys (control cortex
97 9 vs. transgenic cortex 165 11 OD units; P < 0.05 and
control medulla 107 12 vs. transgenic medulla 215 23 OD
units; P < 0.05). Binding sites for bFGF in renal cortex, particu-
larly glomeruli, and along the vasa recta in renal medulla corre-
lated with proteoglycan distribution in these areas by Alcian Blue
staining at pH 1.0 (data not shown) and by immunohistochemistry
for heparan sulfate proteoglycan [131. bFGF binding could be
displaced completely at a higher heparin concentration (300
g/ml) suggesting that all renal bFGF binding sites were sensitive
to heparin displacement (Fig. 5C). Pretreatment of kidney sec-
tions with heparitinase (Seikagaku America, Rockville, Maryland,
USA) at a concentration of 0.01 U/mI for one hour at 37°C
completely abolished binding of bFGF to renal glomeruli and
along the vasa recta in renal medulla.
Renal tubular epithelial cell proliferation
To explore whether bFGF present on the cell surface of the
RTEC could affect epithelial growth, RTECs were isolated from
control and transgenic kidneys with interstitial disease and growth
characteristics were determined in vitro (Fig. 6). Cells expressing
the transgene in vitro, demonstrated spontaneous proliferation at 127,000 5,234 cpm/well P < 0.05) and Figures 6 B and C cell
a more rapid rate than control cells. Figure 6A shows results of number (control: 79,345 7,562 cm2 cells/well vs. transgenic:
thymidine incorporation (control: 72,000 2,340 vs. transgenic: 153,230 12,245 cells/cm2; P < 0.05).
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Fig. 8. Continued.
Identification of bFGF in conditioned medium medium from control and transgenic cells was collected and used
To identify whether biologically active bFGF is present in to stimulate proliferation of several cell targets. Only concen-
conditioned medium from normal and transgenic diseased kid- trated (5 x) conditioned medium from transgenic RTECs stimu-
neys, primary RTEC isolates were cultured in vitro. Conditioned lated the growth of renal epithelial, renal fibroblasts, rat aortic
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smooth muscle cells, and bovine and human endothelial cells;
conditioned medium from control cells had no significant prolif-
erative effects on endothelial cells. Heparin sepharose column
chromatography was performed to characterize further the bFGF
activity (Fig. 7). Fractions eluted from the heparin sepharose
column with 1.5 to 2.0 Nt NaCIwere able to stimulate proliferation
of all cell types in the absence of heparin (Fig. 7 A, B, C).
Antibody directed against bFGF inhibited bovine aortic endothe-
hal cell proliferation in response to conditioned medium (Fig.
7C). Furthermore, bFGF in the absence of other growth factors,
increased thymidine incorporation of primary renal epithelial
target cells approximately fivefold (Fig. 7D) as well as the other
cell lines tested.
bFGF and HIV transgene expression
To ensure that bFGF was expressed by transgenic RTECs in
vitro, we performed Northern analysis of transgenic renal cells in
culture following selection for poly A+ RNA (Fig. 7E). RTECs in
culture expressed the 6.8 kb transcript of bFGF as well as the
proviral mRNA of the three size classes expected, 2kb, 4kb and 7
kb.
bFGF and renal tubular epithelial cell regeneration
Although we had evidence that bFGF could induce epithelial
cell proliferation, it remained unclear whether bFGF could stim-
ulate tubular regeneration. To explore this issue, we cultured
RTECs on matrigel, an artificial basement membrane derived
from EHS tumor. Matrigel has previously been shown to sustain
neonatal mouse RTECs in a differentiated phenotype [42]. Trans-
genic, nontransgenic, and nontransgenic RTECs pretreated for 24
hours with bFGF were cultured on matrigel. As shown in Figure
8, RTECs isolated from transgenic mice (Fig. 8B) formed tubule-
like structures on matrigel within 24 hours of plating, in contrast
to RTECs isolated from normal mice (Fig. 8A). As shown in
Figure 8D, transmission electron microscopy revealed that these
structures were developing tubules with tight junctions, surround-
ing basement membrane, and patent lumens. Control cells pre-
treated with bFGF and plated on matrigel (Fig. 8C) formed
tubules similar to those observed with transgenic RTECs (Fig.
8B). These results suggest that bFGF participates in both RTEC
proliferation and tubule regeneration in transgenic kidneys.
Discussion
Renal disease is increasingly recognized as a complication of
HIV-1 infection, particularly in African Americans [10]. Although
many of the sequelae of HIV-1 infection are related to immuno-
suppression, recent evidence supports a direct role for HIV-1
proteins in the pathogenesis of HIVAN [5, 12, 13]. In humans,
HIVAN presents as nephrotic syndrome with no apparent corre-
lation with CD4 T cell number. Characteristically, clinical pro-
gression to end-stage renal disease is rapid. Histologically, two
essential features appear to dominate the renal pathology: cellular
proliferation and accumulation of extracellular matrix. Microcys-
tic distortion of the renal interstitium is often prominent and
infiltrating inflammatory cells are common. Despite these well-
established pathological features, the mechanisms responsible for
these changes are unknown.
Recently, we have developed a transgenic mouse model of
HIVAN, In this model, we have introduced as a transgene a
deletion mutant of the infectious proviral clone pNL4-3. This
mutant has a deletion of the gag-pol genes but encodes envelope
and the regulatory and accessory genes under the control of the
HIV-1 5' LTR. Since three founders generated offspring with
identical manifestations of renal disease but with different inte-
gration sites by restriction length polymorphism [12], integration
interruption of a critical gene is not the cause of this disease.
Instead, expression of HIV-1 proteins is sufficient to generate the
pathological features of HIVAN in this mouse model in the
absence of other risk factors [2—81 and in the absence of viral
replication [12, 131. In the present study, we have found that the
proliferative tubulointerstitial changes characteristic of the micro-
cystic changes of HIVAN are associated with increased expression
of low affinity binding sites for bFGF in renal interstitium. This
increase in low affinity binding sites facilitates the accumulation of
bFGF in areas of cellular injury and may be critical for inducing
RTEC proliferation.
RTEC injury in transgenic kidney occurred in cells that ex-
pressed both the HIV-I transgene as well as bFGF. Unlike most
other polypeptide growth factors, bFGF lacks a conventional
signal sequence for secretion and, as a result, the mechanisms
responsible for the release of bFGF remain unclear. With cells
that are chronically injured, however, bFGF is efficiently released
[43]. Furthermore, tissue injury potentiates the mitogenic effects
of bFOF [22]. These regenerative processes may be particularly
relevant in HIVAN. In the present study, accumulation of bFGF
appeared to be associated with areas of the renal interstitium that
contained both cell injury and proliferation. We have not excluded
the possibility, however, that other growth factors [44] or HIV-
encoded proteins may have had an additional role in proliferation
as well.
In the present study we found significant alterations in the
distribution and affinity of bFGF binding sites in transgenic
kidney. Previous studies have suggested that the kidney is an
important site for the uptake of exogenously administered bFGF
[45], although the renal distribution of these binding sites has
remained unclear. We have now demonstrated that bFGF binding
sites were localized to renal glomeruhi and vasa recta in the rena'
medulla. The finding in glomeruhi is consistent with other studies
that have demonstrated that glomerular visceral epithelial cells
synthesize both bFGF [23] and HSPG [46]. Thus, this epithehial
cell type possesses a mechanism for the modulation of the local
biological activity of bFGF. Lower affinity binding sites were
found in the renal interstitium of transgenic kidneys in the same
distribution as heparan sulfate proteoglycans. Precedence for
HSPG as a bFGF receptor certainly exists in other biological
systems [47]. Furthermore, heparan sulfate proteoglycans, acting
as bFGF low-affinity receptors [48, 49], may affect the interaction
of bFGF with its high affinity receptor and, as a result, regulate
biological activity. Extrapolating from the findings of our current
study, the large number of low affinity bindings sites in kidney may
be critical for the clearance of bFGF from the circulation partic-
ularly in neoplastic diseases characterized by increased circulating
levels of bFGF [27, 28, 39]. Thus, it is possible that in addition to
the local release of bFGF, extrarenal sources may also contribute
to the deposition of bFGF in kidney.
Proteoglycans have been increasingly recognized as modulators
of renal cell growth [49, 50], and our findings again support an
important role for these extracellular matrix proteins in the
pathogenesis of proliferative tubulointerstitial changes resulting
from HIV-1 infection. TGF-/3 may play an important role in this
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process as well since TGF-13 modulates the production of renal
proteoglycans which bind bFGF [51]. Since TGF-p inhibits the
growth of RTECs in vitro, it is unlikely that a direct effect of
TGF-f3 alone is responsible for the tubulointerstitial proliferative
changes characteristic of HIVAN. By stimulating the proliferation
of renal fibroblasts which produce extracellular matrix proteins,
however, bFGF may affect both the proliferative and fibrotic
processes.
In summary, HIVAN appears to be the result of two distinct
pathological processes, interstitial proliferation and the accumu-
lation of extracellular matrix proteins. In the HIV-1 transgenic
mouse model, an interaction between bFGF and its low affinity
receptors appears to link these two processes. Thus, bFGF
appears to play a critical role in the renal proliferation and
microcystic distortion characteristic of HIV-induced renal disease
and may have a similar role in other renal diseases as well.
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